1Salomon D S, Brandt T, Ciardiello F, et al. Epidermal growth factor-related peptides and their receptors in human malignancies[J]. Crit Rev Oneol Hematol, 1995, 19(3) : 183.
2Fukuoka M, Yano S, Giaceone G, et al. Multi- institutional randomized phase Ⅱ trial of gefitinib for previously treated patients with advanced non - small - cell lung cancer[J]. J Clin Oncol, 2003, 21: 2237.
3Kris M G, Natale R B, Herbst R S, et al. Efficacy of gefi-tinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non - small cell lung cancer[J]. JAMA, 2003, 290: 2149.
4Thatcher N, Chang A, Parikh P, et al. ISEL: A phase Ⅲ Ⅲ survival study comparing gefltinib (lressa) plus best supportive care (BSC) with placebo plus BSC in patients with advanced non small cell lung cancer (NSCLC) who had received one or two prior chemotherapy regimens [ J ]. Proceedings from the 11th World Conference on Lung Cancer, Barcelona, Spain. 2005, Abstract # Pr4.
5Lynch T J, Bell D W, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non - small cell lung cancer to gefitinib [J]. N Engl J Med, 2004, 350: 2129.
7Mok T S, Wu Y L, Thongprasert S, et al. Gefitinib or carboplatin- paelitaxel in pulmonary adenocarcinoma [ J ]. N Engl J Med, 2009, 361(10): 947.
8Zhou C C, Wu Y L, Chen G, et al. Updated efficacy and quality- of - life (QoL) analyses in OPTIMAL, a phase m, randomized, open-label study of first - line erlotinib versus gemeitabine/carboplatin in patients with EGFR- activating mutation - positive ( EGFR Act Mut + ) advanced non-small cell lung cancer (NSCLC)[ J ]. J Clin Oncol, 2011, 29(suppl) : abstr7520.
9GrideUi C, CiardieUo F, Feld R, et al. International multi- center randomized phase Ⅲ study of first - line erlotinib (E) followed by second- line cisplatin plus gemcitabine (CG) versus first- line CG followed by second - line E in advanced non-small cell lung cancer (aNSCLC) : The TORCH trial [J]. J Clin Oncol, 2010, 28(15s) : abstr 7508.
10Kabbinavar F F, Miller V A, Johnson B E, et al. Overall survival (OS) in ATLAS, a phase llIb trial comparing beva- eizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy (ehemo) with B for first- line treat-ment of locally advanced, recurrent, or metastatic non - small cell lung eaneer (NSCLC)[J]. J Clin Oncol, 2010, 28 (15s) : abstr 7526.
二级参考文献12
1Schiller JH. Current standards of care in small-cell and non-smallcell lung cancer[J]. Oncology, 2001, 61 (Suppl 1): 3 - 13.
2Sridhar SS,Seymour L,Shepherd FA. Inhibitors of epidermal-growthfactor receptors: a review of clinical research with a focus on nonsmall-cell lung cancer[J]. Lancet Oncol, 2003, 4(7): 397 -406.
3Jorissen RN, Walker F, Pouliot N, et al. Epidermal growth factor receptor: mechanisms of activation and signaling[J]. Exp Cell Res,2003, 284(1): 31 -53.
4Fukuoka M, Yano S, Giaccone G, et al. Multiinstitutional randomized phase Ⅱ trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer [J]. J Clin Oncol, 2003, 21(12): 2237 -2246.
5Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an in hibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial[J]. JAMA, 2003, 290(16): 2149-2158.
6Wakeling AE, Guy SP, Woodburn JR, et al. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy [J]. Cancer Res, 2002, 62 (20): 5749 -5754.
7Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall-cell lung cancer to gefitinib [J]. N Engl J Med, 2004, 350 (21): 2129-2139.
8Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer:correlation with clinical response to gefitinib therapy[J]. Science,2004, 304 (5676): 1497 - 1500.
9Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib[J]. Proc Natl Acad Sci USA, 2004, 101(36): 13306 -13311.
10Shigematsu H, Lin L, Takahash TI, et al. Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung Cancers[J]. J Natl Cancer Inst, 2005, 97(5):339 - 346.
5Cai Q, Gao Y T, Chow W H, et al. Prospective study of uri- nary prostaglandin E2 metabolite and colorectal cancer risk[J ]. J Clin Oncol, 2006, 24(31): 5010.
6Lanza- Jacoby S, Burd R, Rosato F E Jr, et al. Effect of si- multaneous inhibition of epidermal growth factor recepror and cyclooxygenase 2 in HER - 2/neu positive breast cancer [J]. Clin Cancer Res, 2006, 12(20 pt 1): 6161.
7Brabender J, Park J, Metzger R, et al. Prognostic significence of cyclooxygenase 2 mRNA expression in non - small cell lung cancer[J]. Ann Surg, 2002, 235(3) : 440.
8Esteban J, Robert D, Costanzo A, et al. Lung cancer and cy- clooxygenase- 2[J]. Ann Thorac Surg, 2003, 76(4) : 1327.
9Krysan K, Reckamp K L, Sharma S, et al. The potential and rational for C)X-2 inhibitors in Lung cancer[J]. Anticancer Agents Med Chert, 2006, 6(3) : 209.
10Mascanx C, Mantin B, Paesmans M, et al. Has CA3X - 2 a prognostic role in non - small cell lung cancer A systematic re- view of the literature with meta - analysis of the survival re- sults[J]. BrJ Cancer, 2006, 95(2): 139.
